In the "China Pharmaceutical R&D Blue Book (2024)" produced by Pharmaron, the ranking of drug clinical trial institutions is classified into non BE and BE categories.

<Non BE clinical trial institutions>

In the top 20 rankings of Chinese drug clinical trial institutions in 2023 (ranked by the number of non BE leading units), the concentration of top institutions is relatively evident. Among them, Beijing Cancer Hospital ranks first with 88 non BE trials, but its leading completion rate for non BE trials in the past five years is only 7.31%. Following closely behind is Peking University People's Hospital, with 75 non BE trials and a leading completion rate of 28.73% within 5 years. It is worth noting that among the top 20 non BE trial institutions in 2023, the Second Affiliated Hospital of Anhui Medical University has the highest lead completion rate in the past 5 years, leading a total of 90 non BE trials with a completion rate of 68.89%.

<BE Clinical Trial Institution>

<BE Clinical Trial Institution>>

Among the top 20 clinical BE trial institutions in China in 2023, Henan Zhonghui Cardiovascular Hospital ranked first with 102 trials, and the completion rate of BE trials led by the hospital in the past 5 years reached 67.17%. Secondly, Anhui Jimin Cancer Hospital ranks second with 68 BE trials, and the completion rate of BE trials led in the past 5 years has reached 78.11%. In addition, among the top 20 BE trial institutions in 2023, the Second Affiliated Hospital of Wenzhou Medical University has the highest lead completion rate in the past five years, leading a total of 107 BE trials with a completion rate of 79.44%.

Compared with the completion rate of institutional experiments in the past five years, the average completion rate of institutions conducting BE experiments is 71.39%, while the average completion rate of institutions conducting non BE experiments is only 29.63%. This significant difference indicates that the difficulty and risk of non BE experiments are significantly higher than those of BE experiments, with completion rates even less than half of BE experiments.